Astellas vs. Qilu: Enzalutamide Patent Suit Dismissed in Strategic Venue Pivot
What would you like to do next?
Choose your path based on your current needs:
Learn from this case
Understand the legal analysis, timeline, and key takeaways
RecommendedCheck my product’s risk
Run FTO analysis for your own technology or product
Explore patent landscape
View related patents and competitive intelligence
📋 Case Summary
| Case Name | Astellas Pharma, Inc. et al. v. Qilu Pharmaceutical Co., Ltd. et al. |
| Case Number | 2:24-cv-03747 (E.D. Pa.) |
| Court | Eastern District of Pennsylvania |
| Duration | Aug 2, 2024 – Aug 16, 2024 14 days |
| Outcome | Voluntary Dismissal (Protective Suit) |
| Patents at Issue | |
| Accused Products | Enzalutamide 40 mg and 80 mg tablets (generic Xtandi®) |
Case Overview
The Parties
⚖️ Plaintiffs
Astellas Pharma and its co-plaintiffs collectively hold the intellectual property portfolio covering enzalutamide (Xtandi®), a blockbuster prostate cancer treatment.
🛡️ Defendants
Affiliated entities within a major Chinese pharmaceutical group pursuing generic drug development in the U.S. market via an ANDA filing pathway.
The Patents at Issue
This case involved two key patents covering enzalutamide, a critical androgen receptor inhibitor for prostate cancer:
- • US7709517B2 — Covers foundational aspects of enzalutamide chemistry and therapeutic use.
- • US11839689B2 — A more recent patent covering formulation specifics, reflecting continued lifecycle management.
Developing a generic pharmaceutical?
Ensure your ANDA product doesn’t infringe existing patents, including lifecycle management ones.
The Verdict & Legal Analysis
Outcome: Voluntary Dismissal in Protective Suit
The case was **voluntarily dismissed without prejudice** pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). This means Astellas chose to end the action without a court order, as Qilu had not yet served an answer or motion for summary judgment, and crucially, was **never served** in this Pennsylvania action. Each party bears its own fees and costs, and no damages or injunctive relief were awarded here.
This rapid dismissal was a calculated procedural move, not a reflection of a lack of merit, as the underlying patent infringement litigation continues in the District of New Jersey (C.A. No. 2:24-cv-8217).
Key Legal Issues: The Protective Suit Doctrine
This case exemplifies a **protective suit filing** — a recognized and tactically sound litigation maneuver in pharmaceutical patent practice. When a patent holder initiates litigation in a preferred venue but faces uncertainty about whether the defendant will challenge personal jurisdiction or venue, filing simultaneously in an alternative jurisdiction preserves litigation rights.
Astellas filed the Pennsylvania action as a hedge against a potential venue challenge after filing its primary suit in New Jersey. Once Qilu consented to personal jurisdiction and venue in New Jersey, the Pennsylvania action became redundant and was promptly dismissed without prejudice. The use of FRCP Rule 41(a)(1)(A)(i) was procedurally correct and strategically clean, as no court approval was required.
While this Pennsylvania action produced no precedent on the merits, it underscores the ongoing **venue complexity post-*TC Heartland*** and confirms that protective filings, when transparently handled, remain a valid strategy in Hatch-Waxman Act patent litigation.
Freedom to Operate (FTO) Analysis in Pharma
This rapid dismissal highlights critical venue risks in ANDA litigation. Choose your next step:
📋 Understand Venue Strategy & ANDA Impact
Learn about the specific risks and implications from this litigation.
- Review protective suit best practices post-*TC Heartland*
- Examine Hatch-Waxman litigation trends in oncology
- Analyze related generic enzalutamide filings and strategies
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical technology or product.
- Input your drug compound or formulation specifics
- AI identifies potentially blocking patents (compound, formulation, method)
- Get actionable risk assessment report for ANDA filings
High Risk Area
Enzalutamide formulations & related compounds
2 Patents at Issue
Covering composition and formulation
Active Litigation
Ongoing in District of New Jersey
✅ Key Takeaways
Protective suit filings under FRCP 41(a)(1)(A)(i) remain a legitimate venue-preservation tool when used transparently and dismissed promptly after securing jurisdiction.
Search related case law →Post-*TC Heartland* jurisdiction complexity for foreign pharmaceutical entities warrants proactive multi-venue strategy to ensure litigation rights are preserved.
Explore venue strategy guides →Frequently Asked Questions
The action involved US7709517B2 and US11839689B2, both covering aspects of enzalutamide — the active ingredient in Xtandi® tablets.
Astellas filed this Pennsylvania action as a protective suit one day after initiating the primary litigation in New Jersey. Once Qilu consented to New Jersey jurisdiction, the Pennsylvania case was rendered unnecessary and dismissed without prejudice within 14 days.
The substantive patent infringement action continues in the U.S. District Court for the District of New Jersey as Astellas Pharma Inc. et al. v. Qilu Pharm. (Hainan) Co., Ltd. et al., C.A. No. 2:24-cv-8217.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Lookup — Eastern District of Pennsylvania (Case No. 2:24-cv-03747)
- Google Patents — US7709517B2
- Google Patents — US11839689B2
- Cornell Legal Information Institute — FRCP Rule 41
- FDA — Hatch-Waxman Act Overview
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.